Summit Therapeutics PLC (SMMT NASDAQ) stock market data APIs
$22.7122
-1.55(-6.8%)
as of July 2, 2025
Try our APIs with
free plan!
Summit Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Prev. Close
22.7122
Open
21.158
High
22.7516
Low
21.3247
52 wk Range
6.9-36.91
Market Cap
15 745 M
Shares Outstanding
743 M
EPS
-0.0677
Beta
-1.048
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Summit Therapeutics PLC data using free add-ons & libraries
Get Summit Therapeutics PLC Fundamental Data
Summit Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -235 366 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-29
- EPS/Forecast: -0.0682
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Summit Therapeutics PLC News
New
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Analysts at H.C. Wainwright reaffirmed their Buy rating on Summit Therap...
Summit Therapeutics stock initiated with Buy rating at UBS on cancer drug potential
Investing.com - UBS initiated coverage on Summit Therapeutics plc (NASDAQ:SMMT) with a Buy rating and a $30.00 price target, citing the potential of its lead cancer drug candidate. The stock, currentl...
Summit Therapeutics stock initiated with Buy rating at Clear Street
Investing.com - Summit Therapeutics plc (NASDAQ:SMMT) received a Buy rating initiation from Clear Street with a price target of $30.00. According to InvestingPro data, analyst targets for the stock ra...
Revolution Medicines and Summit Therapeutics in-pact for cancer treatments
[Cancer cells vis] koto_feja/E+ via Getty Images * Revolution Medicines (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]) and Summit Therapeutics (NASDAQ:SMMT [https://seekingalpha.com/symbol/SM...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
